Ground Truth
Inclusion Criteria:Female patients 18 years of age or older;Histologically confirmed serous carcinoma or endometrioid type of endometrial carcinoma (histological documentation of recurrence is not required);Recurrent or persistent progressive disease which is refractory to curative therapy or established treatments and cannot be treated with surgery or radiotherapy;Measurable disease, as defined by RECIST 1.1 criteria;At least one "target lesion" to be used to assess response, as defined by RECIST 1.1 criteria.
Tumors within a previously irradiated field will be designated as "non-target" lesions unless previous progression is documented;Availability of archived tumor tissue sample that can be used for assessment of PrR status by the central laboratory;GOG (Gynecologic Oncology Group) performance status 0-2 (refer to Appendix A);Calculated Glomerular filtration rate ≥ 50 mL/min;Total bilirubin ≤ 2.5 times upper limit of normal (ULN);AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases);Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases);Albumin ≥ 3.0 mg/dL;Ability to take oral medication;Patients able to understand the nature of the study and who are willing to give written informed consent;And for Treatment Period 2 only: 1) Patients participating in Treatment Period 1 must have had disease progression after receiving at least 4 weeks of progestin therapy or 2) Patients must be determined as PrR negative status at Screening.Exclusion Criteria:Mixed histology of the tumor or evidence of tumor histology other than serous carcinoma or endometrioid type of endometrial carcinoma;Concurrent systemic corticosteroid therapy;Concurrent oral contraceptive use / Women of childbearing potential not using highly effective means of contraception;Pregnancy confirmed by pregnancy test / Lactating women;Prior therapy with hormonal progestin agents;Patients who are candidates for treatment with standard chemotherapy agents (there is no limit to the number of lines of chemotherapy);History of blood clot;History of known bleeding disorder (i.e.
disseminated intravascular coagulation or clotting factor deficiency);Major surgery within 4 weeks prior to the start of the study;Patients with clinically significant illnesses which, according to the Investigator, could compromise participation in the study;History of other clinically active malignancies within 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma, or squamous carcinoma of the skin.Known hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine) and excipients;Patients with known brain metastases;Patients currently receiving any other investigational agents;Patients currently receiving any other anticancer therapies;Participation in any other clinical study within the last 4 weeks prior to the start of the study
Prediction
## Modified Inclusion and Exclusion Criteria for Version 2.0 of Clinical Trial Protocol VX-EC-2-02
**Based on the provided text, here are the modified inclusion and exclusion criteria for Version 2.0 of the Clinical Trial Protocol VX-EC-2-02:**
**Inclusion Criteria:**
* **Female patients 18 years of age or older**
* **Histologically confirmed serous carcinoma or endometrioid type of endometrial carcinoma**
* **Recurrent or persistent progressive disease refractory to curative therapy or established treatments**
* **Measurable disease, as defined by RECIST 1.1 criteria**
* **At least one "target lesion" to be used for assessment of response**
* **Tumors within a previously irradiated field will be designated as "non-target" lesions unless previous progression is documented**
* **Availability of archived tumor tissue sample for assessment of PrR status by the central laboratory**
* **GOG performance status 0-2**
* **Calculated Glomerular Filtration Rate (GFR) ≥ 50 mL/min**
* **Total bilirubin ≤ 2.5 times upper limit of normal (ULN)**
* **AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases)**
* **Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases)**
* **Albumin ≥ 3.0 mg/dL**
* **Ability to understand and provide written informed consent**
**Exclusion Criteria:**
* **Mixed histology of the tumor or evidence of tumor histology other than serous carcinoma or endometrioid type of endometrial carcinoma**
* **Concurrent systemic corticosteroid therapy**
* **Concurrent oral contraceptive use or women of childbearing potential not using highly effective contraception**
* **Prior therapy with hormonal progestin agents**
* **Patients who are candidates for treatment with standard chemotherapy agents**
* **History of blood clot**
* **History of known bleeding disorder (e.g., disseminated intravascular coagulation)**
* **Major surgery within 4 weeks prior to the start of the study**
* **Clinically significant illness that could compromise participation in the study**
* **History of other clinically active malignancies within 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin**
* **Known hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine hydrochloride) or excipients**
* **Patients with known brain metastases**
* **Patients currently receiving any other investigational agents**
* **Participation in any other clinical study within the last 4 weeks prior to the start of the study**
**Note:** This is a summary of the modified inclusion and exclusion criteria.
The complete and detailed criteria should be reviewed in the full protocol document.
**Important Considerations:**
* **Version 2.0:** This document reflects the changes made to the inclusion and exclusion criteria for Version 2.0 of the clinical trial protocol.
* **Specificity:** The specific wording and details of the criteria may vary depending on the specific study design and objectives.
* **Clinical Expertise:** It is crucial to consult with a qualified clinical research professional for a comprehensive interpretation of the criteria and their application to individual patients.
* **Informed Consent:** Ensuring that patients fully understand the inclusion and exclusion criteria and the potential risks and benefits of participating in the study is essential.